The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 10, 2010
Filed:
Apr. 14, 2006
Jed Lee Hubbs, Cambridge, MA (US);
Sam Kattar, Medford, MA (US);
Joey Methot, Westwood, MA (US);
Thomas Miller, Brookline, MA (US);
Phieng Siliphaivanh, Brookline, MA (US);
Matthew Stanton, Medfield, MA (US);
Kevin Wilson, West Newton, MA (US);
David J. Witter, Norfolk, MA (US);
Jed Lee Hubbs, Cambridge, MA (US);
Sam Kattar, Medford, MA (US);
Joey Methot, Westwood, MA (US);
Thomas Miller, Brookline, MA (US);
Phieng Siliphaivanh, Brookline, MA (US);
Matthew Stanton, Medfield, MA (US);
Kevin Wilson, West Newton, MA (US);
David J. Witter, Norfolk, MA (US);
Merck Sharp & Dohme Corp., Rahway, NJ (US);
Abstract
The present invention relates to a novel class of hydroxamic acid derivatives. The hydroxamic acid compounds can be used to treat cancer. The hydroxamic acid compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention are also useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the hydroxamic acid derivatives and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the hydroxamic acid derivatives in vivo.